TScan Therapeutics (NASDAQ:TCRX) Cut to “Sell” at Wall Street Zen

Wall Street Zen cut shares of TScan Therapeutics (NASDAQ:TCRX) from a hold rating to a sell rating in a research note released on Saturday.

TCRX has been the subject of a number of other research reports. Needham & Company LLC restated a “buy” rating and set a $9.00 target price on shares of TScan Therapeutics in a report on Tuesday, April 8th. Barclays lowered their target price on TScan Therapeutics from $14.00 to $3.00 and set an “overweight” rating for the company in a report on Friday, March 7th. Wedbush restated an “outperform” rating and set a $7.00 target price on shares of TScan Therapeutics in a report on Tuesday, May 6th. HC Wainwright lowered their target price on TScan Therapeutics from $15.00 to $10.00 and set a “buy” rating for the company in a report on Wednesday, May 7th. Finally, Morgan Stanley restated an “overweight” rating and set a $10.00 target price on shares of TScan Therapeutics in a report on Friday, March 14th. One research analyst has rated the stock with a sell rating and five have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $7.80.

TScan Therapeutics Stock Down 1.3%

Shares of NASDAQ TCRX opened at $1.53 on Friday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 9.56 and a current ratio of 9.56. The firm has a market capitalization of $86.58 million, a price-to-earnings ratio of -1.44 and a beta of 0.98. The stock has a 50 day moving average price of $1.46 and a 200 day moving average price of $2.07. TScan Therapeutics has a 52-week low of $1.02 and a 52-week high of $8.51.

TScan Therapeutics (NASDAQ:TCRX) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.02. The firm had revenue of $2.17 million during the quarter, compared to analyst estimates of $1.62 million. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. Sell-side analysts expect that TScan Therapeutics will post -1.12 earnings per share for the current year.

Insider Activity

In other TScan Therapeutics news, major shareholder Lynx1 Capital Management Lp acquired 1,200,000 shares of the firm’s stock in a transaction dated Tuesday, May 20th. The stock was purchased at an average price of $1.20 per share, for a total transaction of $1,440,000.00. Following the acquisition, the insider now owns 7,946,141 shares in the company, valued at approximately $9,535,369.20. This trade represents a 17.79% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 4.35% of the company’s stock.

Institutional Trading of TScan Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in TCRX. Prudential Financial Inc. acquired a new stake in TScan Therapeutics during the 4th quarter worth about $32,000. ProShare Advisors LLC acquired a new position in shares of TScan Therapeutics in the fourth quarter valued at about $40,000. Hsbc Holdings PLC acquired a new position in shares of TScan Therapeutics in the first quarter valued at about $49,000. Wells Fargo & Company MN increased its holdings in shares of TScan Therapeutics by 41.1% in the fourth quarter. Wells Fargo & Company MN now owns 19,540 shares of the company’s stock valued at $59,000 after purchasing an additional 5,694 shares during the period. Finally, Squarepoint Ops LLC acquired a new position in shares of TScan Therapeutics in the fourth quarter valued at about $59,000. Hedge funds and other institutional investors own 82.83% of the company’s stock.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.